Trial Profile
A randomized, controlled,14-treatment day, multicenter study to determine the optimal efficacious and safe dose of CHF 4226 in a metered dose inhaler in treating patients with chronic obstructive pulmonary disease.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Nov 2021
Price :
$35
*
At a glance
- Drugs Carmoterol (Primary) ; Salmeterol
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors Chiesi Farmaceutici SpA
- 12 Jul 2011 New source identified and integrated (European Clinical Trials Database, EudraCT2006-000531-10 ).
- 12 Jul 2011 New source identified and integrated (European Clinical Trials Database, EudraCT2006-000531-10 ).
- 10 Mar 2008 New trial record.